The Oncology Institute, Inc. TOI Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Other Operating Income by Business | ||||||
| Clinical trials & other | $3.28M-22.7% | $4.24M-22.4% | $5.46M-16.6% | $6.54M-2.2% | $6.69M-4.5% | |
| Patient services | $17.43M-1.5% | $17.7M+23.9% | $14.28M+6.0% | $13.47M-9.8% | $14.94M+23.0% | |
| Total operating revenue by Product | ||||||
| Capitated revenue | $89.92M+11.7% | $80.48M+8.2% | $74.42M+8.4% | $68.66M+0.2% | $68.51M-0.3% | |
| Clinical trials & other | $3.33M-27.0% | $4.56M-27.8% | $6.32M-18.8% | $7.79M-4.2% | $8.12M-5.7% | |
| FFS revenue | $145.09M-2.3% | $148.51M+2.5% | $144.96M+3.3% | $140.27M+2.4% | $136.98M+0.6% | |
| Patient services | $235.01M+2.6% | $228.99M+4.4% | $219.37M+5.0% | $208.93M+1.7% | $205.5M+0.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does The Oncology Institute, Inc. break its business down?
- The Oncology Institute, Inc. (TOI) reports other operating income by business across 3 parts — Clinical trials & other, Patient services and Specialty pharmacy. Each is extracted from the segment footnotes and tracked over time.
- Where does The Oncology Institute, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in The Oncology Institute, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
